There is good news for oncology specialist Innate Pharma (Euronext: IPH), which has been told by the US regulator that a partial clinical hold on the Phase II TELLOMAK study has been lifted.
The Parisian biotech is free to continue evaluating lacutamab as an option for people with advanced T-cell lymphomas, after a quality assessment of the study drug passed the agency’s tests.
Shares in the company were changing hands 4% higher in Wednesday morning trading.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze